Actithera Norway AS

Actithera Norway AS, based in Norway, is a biotechnology firm focused on developing advanced cancer treatments through innovative radioligand therapy, utilizing proprietary molecular design to enhance therapeutic efficacy. Founded in 2021 and headquartered in Paris, France, Actithera Norway AS specializes in radioligand therapy for cancer treatment. The company recently raised USD 75. 5 mn in a Series A funding round on July 9, 2025, co-led by 4BIO Capital Partners, M Ventures, Hadean Ventures, and Sofinnova Partners.

The founder's background and any previous entrepreneurial ventures are not publicly available. Actithera specializes in advanced cancer treatment through its innovative radioligand therapy (RLT) offerings. The company employs proprietary molecular design techniques to create best-in-class compounds that specifically target tumors while minimizing exposure to healthy tissues. This personalization of therapy is achieved by initially imaging patients to determine the appropriate treatment based on tracer uptake.

Actithera's RLT products are designed to be more effective and better tolerated than traditional cancer therapies, significantly enhancing the quality of life for patients. The company's products are being developed for clinical trials and are targeted towards healthcare providers and institutions globally, focusing on markets in North America, Europe, and parts of Asia. Actithera's revenue model is primarily structured around partnerships and collaborations within the healthcare sector, specifically targeting hospitals and oncology clinics that administer their radioligand therapies. The company may engage in direct sales of its products to these institutions, which are expected to include flagship therapies designed for various types of cancers.

Transactions are likely governed by negotiated pricing agreements tailored to the specific needs of healthcare providers, enabling volume purchases that can lead to cost efficiencies. Revenue generation is supported through ongoing partnerships that may involve shared clinical trial data and joint ventures in product development, ensuring alignment with the evolving needs of cancer treatment and management. Actithera plans to use the USD 75. 5 mn raised in its Series A funding round to advance its lead FAP-targeting radioligand into clinical trials and to expand its preclinical pipeline and discovery platform.

The company aims to launch upcoming products designed for various cancer types while targeting expansion into North American, European, and parts of Asian markets by 2026.